{
    "id": 32590,
    "fullName": "MEN1 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "MEN1 positive indicates the presence of the MEN1 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 4221,
        "geneSymbol": "MEN1",
        "terms": [
            "MEN1",
            "MEAI",
            "SCG2"
        ]
    },
    "variant": "positive",
    "createDate": "02/13/2020",
    "updateDate": "02/13/2020",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 20400,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MI-503 and Nexavar (sorafenib) treatment synergistically inhibited growth of a MEN1 and KMT2A-positive hepatocellular carcinoma cell line in culture, and inhibited tumor growth in a cell line xenograft model (PMID: 29142068).",
            "molecularProfile": {
                "id": 35164,
                "profileName": "KMT2A pos MEN1 pos"
            },
            "therapy": {
                "id": 9343,
                "therapyName": "MI-503 + Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17829,
                    "pubMedId": 29142068,
                    "title": "Pharmacologic Inhibition of the Menin-MLL Interaction Leads to Transcriptional Repression of PEG10 and Blocks Hepatocellular Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29142068"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20416,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MI-503 treatment inhibited Men1 and Kmt2a interaction, led to inhibition of AR signaling and induction of apoptosis in KMT2A- and MEN1-positive prostate cancer cell lines in culture, and tumor growth inhibition in cell line xenograft models (PMID: 25822367).",
            "molecularProfile": {
                "id": 35164,
                "profileName": "KMT2A pos MEN1 pos"
            },
            "therapy": {
                "id": 6006,
                "therapyName": "MI-503",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17831,
                    "pubMedId": 25822367,
                    "title": "Targeting the MLL complex in castration-resistant prostate cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25822367"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20395,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MI-503 treatment inhibited migration and growth of a MEN1- and KMT2A-positive hepatocellular carcinoma cell line in culture, and inhibited tumor growth in a cell line xenograft model (PMID: 29142068).",
            "molecularProfile": {
                "id": 35164,
                "profileName": "KMT2A pos MEN1 pos"
            },
            "therapy": {
                "id": 6006,
                "therapyName": "MI-503",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17829,
                    "pubMedId": 29142068,
                    "title": "Pharmacologic Inhibition of the Menin-MLL Interaction Leads to Transcriptional Repression of PEG10 and Blocks Hepatocellular Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29142068"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20420,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MI-503 and Xtandi (enzalutamide) combination treatment resulted in greater tumor growth inhibition compared to MI-503 treatment alone in cell line xenograft models of AR-, KMT2A- and MEN1-positive prostate cancer (PMID: 25822367).",
            "molecularProfile": {
                "id": 35165,
                "profileName": "AR pos KMT2A pos MEN1 pos"
            },
            "therapy": {
                "id": 9344,
                "therapyName": "Enzalutamide + MI-503",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17831,
                    "pubMedId": 25822367,
                    "title": "Targeting the MLL complex in castration-resistant prostate cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25822367"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 35161,
            "profileName": "MEN1 positive",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35164,
            "profileName": "KMT2A pos MEN1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35165,
            "profileName": "AR pos KMT2A pos MEN1 pos",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}